# Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Source: https://onco.cc/trials/nct03937154/  
OnCo record `nct03937154` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Romiplostim in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer is a phase 3 interventional study registered as NCT03937154 by Amgen, with 145 participants enrolled, started 2020-02-26 and due to reach its primary completion in 2026-03-10. Interventions recorded: Romiplostim and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03937154
- Phase: 3
- Setting: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
- Sponsor: Amgen
- Enrolled: 145

## Sources

- ClinicalTrials.gov NCT03937154: https://clinicaltrials.gov/study/NCT03937154

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Romiplostim](https://onco.cc/drugs/romiplostim/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct03937154.json